1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow siltuximab: new trials by email Literature Review of siltuximab trials Research Report on siltuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-10-30 |
| SILtuximab in Viral ARds (SILVAR) Study Siltuximab, Normal Saline - Acute Respiratory Distress Syndrome, Lung Diseases | Phase 3 | Terminated | RECORDATI GROUP | 555 | 2020-11-13 | 2021-04-19 |
| Treatment of COVID-19 Patients With Anti-interleukin Drugs Usual Care, Anakinra, Siltuximab - COVID-19 | Phase 3 | Completed | University Hospital, Ghent | 342 | 2020-04-03 | 2023-03-14 |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Placebo, Velcade and dexamethasone, Siltuximab, Velcade and dexamethasone - Multiple Myeloma | Phase 3 | Withdrawn | Centocor, Inc. | 2011-07-01 | 2013-01-28 |
Respiratory Distress Syndrome (2) · Acute Lung Injury (1) · Burkitt Lymphoma (1) · COVID-19 (1) · Hypoxia (1) · Lung Diseases (1) · Multiple Myeloma (1) · Pneumonia (1) · Recurrence (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Severe Acute Respiratory Syndrome (1)
Centocor, Inc. (1) · Merck Sharp & Dohme LLC (1) · RECORDATI GROUP (1) · University Hospital, Ghent (1)
Belgium (2) · Canada (2) · Netherlands (2) · United States (2) · Australia (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · France (1) · Greece (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · New Zealand (1)
Bart Lambrecht, MD, PhD (1) · Zainab Shahid, MD, Ph.D (1)
PMID 32493441, PMID 33935163, PMID 34756178, PMID 35080773
2025 (1)